We use analytics and advertising cookies, which you can accept or reject; see our privacy policy.

Current choice:

Purinergic (P2Y) Receptors

P2Y receptor antagonists and agonists act on purinergic G protein-coupled receptors for extracellular nucleotides. The eight human P2Y receptors respond to adenosine diphosphate (ADP), adenosine triphosphate (ATP), uridine triphosphate (UTP) or related nucleotides. The first member, now called P2Y1, was cloned from chick brain in 1993 as a G protein-coupled ATP receptor. In 2001 the platelet ADP receptor P2Y12 was identified as the target of thienopyridine antithrombotic compounds. Clopidogrel hydrogen sulfate and prasugrel are thienopyridine prodrugs, whereas ticagrelor, cangrelor and AZD1283 block P2Y12 without metabolic activation. BPTU is an allosteric P2Y1 antagonist, and MRS 2578 blocks P2Y6, a receptor activated by uridine diphosphate. Ligand-gated nucleotide channels are listed separately under the sibling category P2X Receptor.

1 Item

  • PSB-22219
    Cat. No.
    A62844
    CAS No.
    1404529-43-6

    PSB-22219

    PSB-22219 is a highly selective non-nucleotidic ligand for the P2Y12 receptor, with a binding affinity of KD=4.57 nM. This compound demonstrates significant promise in the study of P2Y12 receptor-mediated neuroinflammation, making it a valuable tool for research applications in neurobiology and related fields. Its specificity and efficacy facilitate investigations into the role of P2Y12 in various pathological conditions.

    In stock View Details
    5 mg
    $350.00
    10 mg
    $650.00
    All 3 sizes

1 Item

Added to your cart

View Cart Checkout

    Loading...